$355.1 M

CBMG Mkt cap, 14-Dec-2018

$70.4 K

Cellular Biomedicine Group Revenue Q3, 2018
Cellular Biomedicine Group Gross profit (Q3, 2018)32.9 K
Cellular Biomedicine Group Gross profit margin (Q3, 2018), %46.8%
Cellular Biomedicine Group Net income (Q3, 2018)-12.7 M
Cellular Biomedicine Group EBIT (Q3, 2018)-12.8 M
Cellular Biomedicine Group Cash, 30-Sep-201857.9 M

Cellular Biomedicine Group Income Statement

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

2.5m627.9k336.8k

Cost of goods sold

1.9m860.4k162.2k

Gross profit

625.1k(232.5k)174.6k

Gross profit Margin, %

25%(37%)52%

Sales and marketing expense

127.7k709.2k425.0k360.8k

R&D expense

1.9m7.6m11.5m14.6m

General and administrative expense

9.3m13.1m11.7m12.8m

Operating expense total

17.2m23.4m29.0m27.9m

EBIT

(13.1m)(20.8m)(28.4m)(27.6m)

EBIT margin, %

(832%)(4525%)(8187%)

Interest expense

257.8k

Interest income

3.2k42.2k78.9k133.6k

Pre tax profit

(13.5m)(20.2m)(28.2m)

Income tax expense

(344.4k)

Net Income

(13.8m)(19.4m)(28.2m)(25.5m)

Cellular Biomedicine Group Balance Sheet

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Cash

7.2m14.9m39.3m21.6m

Accounts Receivable

10.6k630.3k412.7k

Inventories

119.1k390.9k

Current Assets

7.6m16.7m40.7m24.5m

PP&E

1.0m2.8m4.1m13.0m

Goodwill

3.3m7.7m7.7m7.7m

Total Assets

17.6m49.5m68.6m61.2m

Accounts Payable

213.9k260.9k216.2k225.3k

Current Liabilities

2.2m3.0m2.4m3.7m

Total Liabilities

2.2m3.1m2.7m3.9m

Additional Paid-in Capital

37.9m103.8m152.5m172.7m

Retained Earnings

(22.4m)(57.3m)(85.5m)(111.0m)

Total Equity

15.4m46.4m65.9m57.3m

Financial Leverage

1.1 x1.1 x1 x1.1 x

Quarterly

USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

4.9m2.1m3.5m6.0m13.6m9.8m31.1m23.7m20.1m15.7m47.5m44.1m33.4m27.3m16.3m45.6m24.8m57.9m

Accounts Receivable

34.6k24.0k175.1k340.0k445.2k410.8k582.7k245.1k264.8k813.1k

Inventories

38.8k30.4k40.0k133.7k156.5k347.8k277.9k400.1k422.1k486.3k313.8k253.2k

Current Assets

5.2m2.5m3.8m6.6m14.2m11.1m32.6m25.5m21.7m17.7m49.2m45.3m35.3m29.4m19.1m48.7m37.5m70.3m

PP&E

1.2m1.1m1.1m895.3k819.9k1.3m1.4m1.3m1.7m2.7m3.2m3.1m4.4m7.0m11.0m14.6m14.1m14.3m

Goodwill

6.8m6.8m6.8m3.3m7.7m7.7m7.7m7.7m7.7m7.7m7.7m7.7m7.7m7.7m7.7m7.7m7.7m

Total Assets

15.5m12.6m16.5m17.8m26.2m41.6m57.9m67.1m61.9m71.3m87.5m72.7m63.6m59.9m53.6m86.7m75.8m106.4m

Accounts Payable

115.9k156.3k157.0k177.4k109.1k224.4k160.2k106.6k146.4k208.9k136.4k220.2k782.5k1.2m1.2m331.8k387.9k484.0k

Current Liabilities

2.9m2.3m1.9m1.8m2.5m4.9m5.0m5.2m4.7m3.2m2.2m1.9m2.0m4.5m3.9m5.2m4.8m5.9m

Total Liabilities

3.0m2.4m1.9m1.8m2.5m5.3m5.5m5.0m6.6m2.5m1.9m2.4m4.5m3.9m5.4m4.9m6.4m

Additional Paid-in Capital

25.9m26.2m31.4m39.4m49.8m66.2m95.8m99.1m101.3m109.9m148.8m150.9m154.0m155.6m157.0m205.1m206.8m249.5m

Retained Earnings

(12.9m)(15.4m)(16.0m)(22.9m)(29.5m)(32.4m)(42.2m)(47.2m)(52.3m)(61.5m)(68.7m)(79.4m)(91.7m)(97.9m)(104.1m)(119.5m)(128.7m)(141.5m)

Total Equity

12.5m10.2m14.6m16.0m23.7m36.3m52.7m61.6m56.9m64.7m85.0m70.8m61.2m55.4m49.8m81.3m70.9m100.0m

Financial Leverage

1.2 x1.2 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x

Cellular Biomedicine Group Cash Flow

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Net Income

(13.8m)(19.4m)(28.2m)(25.5m)

Depreciation and Amortization

841.2k2.1m2.6m3.0m

Accounts Receivable

50.2k(497.9k)537.2k(160.6k)

Inventories

(81.9k)(142.5k)514.7k

Accounts Payable

(166.0k)(28.2k)(814.0)

Cash From Operating Activities

(8.5m)(11.8m)(15.9m)(18.6m)

Purchases of PP&E

(1.9m)(2.7m)(10.2m)

Cash From Investing Activities

(153.0k)(7.7m)(2.7m)(10.2m)

Cash From Financing Activities

11.6m19.6m43.3m10.8m

Income Taxes Paid

108.1k6.7k2.5k

Cellular Biomedicine Group Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Cellular Biomedicine Group Employee Rating

5.01 votes
Culture & Values
5.0
Work/Life Balance
5.0
Senior Management
5.0
Salary & Benefits
3.0
Career Opportunities
5.0
Source